SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally.
+ 1 more risk
Flawless balance sheet and good value.
Share Price & News
How has SHL Telemedicine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SHLTN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SHLTN exceeded the Swiss Healthcare industry which returned -20.2% over the past year.
Return vs Market: SHLTN underperformed the Swiss Market which returned -5.4% over the past year.
Price Volatility Vs. Market
How volatile is SHL Telemedicine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDo You Like SHL Telemedicine Ltd. (VTX:SHLTN) At This P/E Ratio?
2 months ago | Simply Wall StIs SHL Telemedicine Ltd. (VTX:SHLTN) Overpaying Its CEO?
3 months ago | Simply Wall StSHL Telemedicine Ltd. (VTX:SHLTN) Is Employing Capital Very Effectively
Is SHL Telemedicine undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SHLTN (CHF5.5) is trading below our estimate of fair value (CHF56.62)
Significantly Below Fair Value: SHLTN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SHLTN is good value based on its PE Ratio (11x) compared to the Healthcare industry average (19.1x).
PE vs Market: SHLTN is good value based on its PE Ratio (11x) compared to the Swiss market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SHLTN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SHLTN is overvalued based on its PB Ratio (1.8x) compared to the XE Healthcare industry average (1.6x).
How is SHL Telemedicine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SHL Telemedicine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether SHL Telemedicine is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- SHL Telemedicine competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has SHL Telemedicine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SHLTN has high quality earnings.
Growing Profit Margin: SHLTN's current net profit margins (12.9%) are lower than last year (18.8%).
Past Earnings Growth Analysis
Earnings Trend: SHLTN has become profitable over the past 5 years, growing earnings by 30.8% per year.
Accelerating Growth: SHLTN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SHLTN had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Healthcare industry average (-3.2%).
Return on Equity
High ROE: SHLTN's Return on Equity (16.5%) is considered low.
How is SHL Telemedicine's financial position?
Financial Position Analysis
Short Term Liabilities: SHLTN's short term assets ($17.6M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: SHLTN's short term assets ($17.6M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: SHLTN's debt to equity ratio (4.5%) is considered satisfactory.
Reducing Debt: SHLTN's debt to equity ratio has reduced from 39.4% to 4.5% over the past 5 years.
Debt Coverage: SHLTN's debt is well covered by operating cash flow (1219.8%).
Interest Coverage: SHLTN earns more interest than it pays, so coverage of interest payments is not a concern.
What is SHL Telemedicine's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SHLTN's dividend (17.76%) is higher than the bottom 25% of dividend payers in the Swiss market (2.05%).
High Dividend: SHLTN's dividend (17.76%) is in the top 25% of dividend payers in the Swiss market (4.46%)
Stability and Growth of Payments
Stable Dividend: SHLTN has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: SHLTN's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (194.6%), SHLTN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yoav Rubinstein (46yo)
Mr. Yoav Rubinstein has been the Chief Executive Officer at SHL Telemedicine Ltd. since June 1, 2017. Mr. Rubinstein served as an Investment Manager of Apax Israel Investment Fund. He focused on buyouts an ...
CEO Compensation Analysis
Compensation vs Market: Yoav's total compensation ($USD1.04M) is above average for companies of similar size in the Swiss market ($USD697.22K).
Compensation vs Earnings: Insufficient data to compare Yoav's compensation with company performance.
|Chief Executive Officer||3yrs||US$1.04m||no data|
|Chief Financial Officer||3yrs||no data||no data|
|Chief Technology Officer||3.17yrs||no data||no data|
|Managing Director of SHL Telemedizin||0.92yr||no data||no data|
Experienced Management: SHLTN's management team is considered experienced (3 years average tenure).
|Independent Director||1.33yrs||US$26.14k||no data|
|Chairman of the Board||1.33yrs||US$2.54k||no data|
|Independent Director||2.83yrs||US$34.02k||no data|
Experienced Board: SHLTN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SHL Telemedicine Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: SHL Telemedicine Ltd.
- Ticker: SHLTN
- Exchange: SWX
- Founded: 1987
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: CHF57.767m
- Shares outstanding: 10.50m
- Website: https://www.shl-telemedicine.com
Number of Employees
- SHL Telemedicine Ltd.
- Ashdar Building
- 90 Yigal Alon Street
- Tel Aviv
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SHLTN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Nov 2000|
|SZO||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2000|
|SMDC.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Nov 2000|
|SHLTNZ||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||CHF||Nov 2000|
|0QMX||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Nov 2000|
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12-lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter; Cardio’B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and Internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company was founded in 1987 and is headquartered in Tel Aviv, Israel.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 23:39|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.